Inconsistencies regarding the type or level of expression of adrenergic receptors and the effect of their agonists in breast cancer cells thus limit confidence that modulation of βAR signaling in cancer cells may be of any solid predictive and therapeutic value, although this needs to be further examined. This evidence concerns the gene ADRB2 and breast cancer.